Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 484,877,888
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • EBIT $ 17,235 M
  • EBITDA $ 18,602 M
  • 60-Month Beta 0.40
  • Price/Sales 14.24
  • Price/Cash Flow 35.52
  • Price/Book 27.02

Options Overview Details

View History
  • Implied Volatility 55.11% ( +1.18%)
  • Historical Volatility 29.51%
  • IV Percentile 99%
  • IV Rank 99.16%
  • IV High 55.37% on 11/20/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.30
  • Today's Volume 56,602
  • Volume Avg (30-Day) 40,241
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 567,969
  • Open Int (30-Day) 480,272

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.88
  • Number of Estimates 4
  • High Estimate 0.93
  • Low Estimate 0.86
  • Prior Year 0.71
  • Growth Rate Est. (year over year) +23.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.42 +8.64%
on 11/18/24
112.52 -4.01%
on 12/11/24
+6.27 (+6.16%)
since 11/15/24
3-Month
99.42 +8.64%
on 11/18/24
135.20 -20.11%
on 09/19/24
-23.99 (-18.17%)
since 09/17/24
52-Week
98.52 +9.63%
on 12/18/23
148.15 -27.09%
on 06/25/24
+10.91 (+11.24%)
since 12/15/23

Most Recent Stories

More News
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?

AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble Therapeutics, which will add the latter’s lead pipeline candidate, an oral...

NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
ABBV : 175.38 (+2.18%)
5 Top European Stocks to Buy Before 2025

With the U.S. stock market reaching all-time highs, it might be a good idea to check out some quality European stocks.

NVO : 108.01 (-0.04%)
LVMHF : 668.2100 (+0.71%)
LRLCY : 72.1700 (+0.60%)
ASML : 735.19 (+1.77%)
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought...

NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
3 Growth Stocks That Can Be No-Brainer Buys in 2025

Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations. Investing in a stock at a steep premium can limit the return you can earn from it, or...

PDD : 102.42 (+2.82%)
NVO : 108.01 (-0.04%)
CCL : 25.72 (-0.73%)
AMZN : 231.15 (-0.76%)
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study

Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression...

AZN : 67.18 (+1.43%)
NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
2 No-Brainer Growth Stocks to Buy and Hold Through 2025 and Beyond

The stock market performed well in 2024 despite lingering economic issues and geopolitical instability. The bull run remains in full swing, and although investors can't predict what will happen in 2025,...

GOOG : 197.12 (-0.52%)
GOOGL : 195.42 (-0.63%)
NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
VEEV : 226.41 (+0.77%)
4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

AA : 38.44 (-0.05%)
NVDA : 130.39 (-1.22%)
HIMS : 31.12 (-0.42%)
NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
LRN : 107.60 (-1.23%)
VICR : 52.92 (-6.44%)
MPWR : 628.22 (-0.06%)
Warning: This Skyrocketing Stock Has a Hidden Risk

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the company reported solid results from trials of a candidate meant to address one of...

VKTX : 46.70 (-1.12%)
NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
GS : 574.68 (-1.99%)
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now

According to a sneak peek of the data from one of Eli Lilly 's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful...

NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

VKTX : 46.70 (-1.12%)
CRBP : 14.29 (+0.07%)
NVO : 108.01 (-0.04%)
$SPX : 6,050.61 (-0.39%)
LLY : 778.62 (-0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 110.02
2nd Resistance Point 109.51
1st Resistance Point 108.76
Last Price 108.01
1st Support Level 107.49
2nd Support Level 106.98
3rd Support Level 106.23

See More

52-Week High 148.15
Fibonacci 61.8% 129.19
Fibonacci 50% 123.33
Fibonacci 38.2% 117.48
Last Price 108.01
52-Week Low 98.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar